Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
LRMR
LRMR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LRMR News
Larimar Therapeutics Prices Upsized Public Offering of 20 Million Shares
Feb 26 2026
NASDAQ.COM
Marriott Vacations Reports Strong Q4, Shares Surge
Feb 26 2026
Benzinga
Larimar Therapeutics Prices Upsized Public Offering of 20M Shares at $5.00 Each
Feb 26 2026
seekingalpha
Wall Street Opens Cautiously Amid China Market Concerns
Feb 26 2026
stocktwits
Larimar Therapeutics Prices $100 Million Stock Offering Following FDA Breakthrough Designation
Feb 26 2026
stocktwits
Larimar Therapeutics Prices Upsized Public Offering
Feb 26 2026
Newsfilter
Larimar Therapeutics Launches $75 Million Public Offering
Feb 25 2026
seekingalpha
Larimar Therapeutics Launches $75 Million Public Offering
Feb 25 2026
Yahoo Finance
Larimar Therapeutics Shares Surge on Analyst Upgrades
Feb 25 2026
Benzinga
Semiconductor Stocks Show Strong Gains
Feb 24 2026
NASDAQ.COM
U.S. Stocks Rise with Dow Jones Up Over 400 Points
Feb 24 2026
Benzinga
Kraig Biocraft's Spider Silk Technology Gains Attention
Feb 24 2026
Globenewswire
Kraig Biocraft Laboratories Featured on National Geographic Cover
Feb 24 2026
Newsfilter
FDA Grants Breakthrough Therapy Designation to Larimar's Nomlabofusp for Friedreich’s Ataxia
Feb 24 2026
stocktwits
U.S. Stocks Mixed in Morning Trade; Dow Jones Up Over 100 Points
Feb 24 2026
Benzinga
Larimar Receives FDA Breakthrough Therapy Designation for Nomlabofusp
Feb 24 2026
seekingalpha
Show More News
